What is it?
What is yohimbe bark extract?
1Yohimbe bark extract is a botanical preparation made from Pausinystalia yohimbe bark. Its supplement relevance comes mainly from yohimbine and related alkaloids, but the bark extract should be evaluated as a variable source product rather than as purified yohimbine HCl.
What yohimbe is marketed for
8Yohimbe-containing supplements are commonly marketed around sexual wellness, energy, body composition, fat-loss and athletic-performance claims. The available human evidence for bark/extract supplements is too limited and product-dependent to support reliable nootropic, weight-loss or performance expectations.
Evidence by use case
2Most controlled pharmacology and historical clinical discussion concerns purified yohimbine HCl, not commercial yohimbe bark extract. For the bark/extract page, the most useful evidence signal is that products can vary substantially in alkaloid content and that safety concerns are documented more clearly than practical benefits.
Names, aliases and forms
Potential effects and evidence map
Evidence for yohimbe bark extract is indirect and product-dependent. Purified yohimbine HCl has a separate pharmacology and historical clinical context, but bark/extract supplements have limited human evidence for practical benefit and stronger evidence for labeling variability and safety concern.
Yohimbe bark/extract is marketed for sexual wellness, but its human evidence is insufficient; findings with purified yohimbine HCl do not establish extract benefit.
Yohimbe is marketed in performance and pre-workout contexts, but evidence for athletic-performance benefit from dietary supplements is limited and inconsistent.
Adrenergic stimulation may feel energizing to some users, but this is not reliable evidence of a useful cognitive-performance benefit and overlaps with safety risk.
Typical dosages and timing
A 49-product analysis reported yohimbine per recommended serving from none detected to 12.1 mg. Use this as product-content context only: it is not a recommended yohimbe bark extract dose, and bark or extract milligrams cannot be converted into a dependable yohimbine exposure without testing.
Safety, side effects and risk profile
Known cardiovascular hazards include tachycardia, hypertension and potentially serious rhythm or ischemic events. NIH ODS advises medical supervision for yohimbe because serious adverse effects are possible.
Stimulant-like adrenergic effects can include anxiety, restlessness, agitation and sleep disruption.
Interaction risk is meaningful with antidepressants, cardiovascular medicines and stimulant combinations.
Pregnancy and breastfeeding are separate avoidance cautions; evidence does not support a numeric risk estimate for these populations.
Headache, dizziness, flushing and sweating are reported with yohimbine-containing products.
Regulatory treatment varies by jurisdiction and is stricter in the EU food context than in the U.S. dietary-supplement framing.
Commercial yohimbe products can vary enough that label-based exposure estimates are unreliable without alkaloid disclosure or testing.
A retrospective poison-control series of 238 symptomatic adults mainly involved herbal yohimbine products. Tachycardia, hypertension, agitation and gastrointestinal symptoms were prominent, with some serious outcomes. The selected cases do not show how often events occur among all users or define a safe bark dose.
Because yohimbine has stimulant-like adrenergic effects, yohimbe products can be a poor fit for people prone to anxiety, panic, PTSD symptoms, restlessness or insomnia.
Reported adverse effects include nausea or other stomach symptoms, headache, flushing, sweating, dizziness and agitation. These effects may be more unpredictable when the active alkaloid content is not declared.
Official summaries and poison-control data describe serious yohimbine-related concerns including seizures, heart attacks and need for medical care in some reports. This does not establish a predictable dose threshold for bark extracts.
Interactions and cautions
Avoid yohimbe with monoamine oxidase inhibitors or tricyclic antidepressants, and use extra caution around other psychiatric medicines because adrenergic stimulation can worsen anxiety-like or cardiovascular effects.
Yohimbe may be a poor fit with blood-pressure, heart-rate or cardiovascular medicines unless a qualified clinician is involved, because the ingredient category is specifically linked with blood pressure and heart-rate concerns.
Combining yohimbe with caffeine, synephrine, rauwolscine, ephedrine-like stimulants, stimulant medicines or decongestants can raise the practical cardiovascular and overstimulation risk.
Pregnancy and breastfeeding warrant avoidance because oral safety is not established and harm is possible. Seizure history and prior serious stimulant reactions add reasons for professional assessment before exposure.
Legal and regulatory status
As of October 2026, yohimbe appears in the United States dietary-supplement market, which does not mean FDA premarket approval. U.S. over-the-counter products containing yohimbine require FDA approval for erectile-dysfunction drug claims; ordinary supplement marketing does not provide that authorization.
As of October 2026, the European Union food rule in Commission Regulation (EU) 2019/650 places yohimbe bark and its preparations in Part A of Annex III to Regulation (EC) No 1925/2006, prohibiting their use in foods. This botanical food restriction is not a worldwide rule or a blanket description of every isolated medicinal yohimbine product.
How it compares
Botanical bark or bark-extract product. Alkaloid amount, extract ratio, plant identity and label accuracy can vary, so bark milligrams cannot be converted into a dependable yohimbine dose.
Isolated yohimbine salt with a defined compound amount. That offers a different dose and pharmacology context from bark extract, while cardiovascular and interaction concerns still apply.
Studies or safety notes about purified yohimbine should not be automatically applied to an unstandardized bark product. A label that only lists bark-extract milligrams leaves the active yohimbine exposure uncertain.
Practical buying and quality notes
- Compare extract mass and actual yohimbine disclosure separately. Price per gram of bark extract is not a price per milligram of active alkaloid, and an extract ratio alone cannot establish the latter. Verify package size and serving information on the merchant label before using catalog price normalization.2
- Look for extract ratio, standardization basis, plant identity and lot-specific third-party testing. Finished-product testing matters because yohimbine can be hard to infer from the ingredient name alone.7
- Avoid stimulant blends that stack yohimbe with caffeine, synephrine, rauwolscine or other aggressive pre-workout/fat-loss ingredients.8
- Do not assume a product is safer because it is called natural bark extract. For this ingredient, natural-source wording does not remove alkaloid, interaction or labeling risk.1
FAQ
Is yohimbe the same as yohimbine?
1No. Yohimbe is the botanical bark or bark extract. Yohimbine is one alkaloid from that source and is sometimes supplied as the purified HCl salt. These products have different composition and evidence; their milligram amounts are not interchangeable.
How much yohimbine is in yohimbe bark extract?
2It depends on the product. Analyses of commercial supplements found wide variation, and some labels do not clearly disclose yohimbine content. Bark milligrams or extract milligrams are not the same thing as milligrams of purified yohimbine.
Is yohimbe safe?
1Yohimbe is a high-caution supplement category. It has documented safety concerns around blood pressure, heart rate, anxiety-like effects, GI symptoms, headaches, interactions, pregnancy/lactation and rare serious events. Product variability makes safety harder to judge from a label alone.
Does yohimbe work for weight loss or athletic performance?
8Evidence for yohimbe- or yohimbine-containing dietary supplements in weight-loss and athletic-performance contexts is limited and inconsistent. The safety and stimulant-stacking concerns are more actionable than the claimed benefit.
Can yohimbe be used for erectile dysfunction?
1Bark extract has insufficient human evidence for erectile-function benefit. Historical clinical research on purified yohimbine HCl does not establish equivalent effects for a variable botanical extract. In the United States, erectile-dysfunction drug claims need FDA approval.
What should a yohimbe label show?
7A stronger label should identify the plant source, extract ratio or standardization, actual yohimbine alkaloid amount, serving size, warnings and ideally third-party testing. A label that only lists bark extract milligrams leaves the active exposure unclear.
Who should avoid yohimbe?
1People who are pregnant or breastfeeding, people using MAOIs or tricyclic antidepressants, and people with cardiovascular conditions, blood pressure issues, anxiety/panic vulnerability, PTSD symptoms, seizure history or stimulant sensitivity should avoid self-directed yohimbe use.
What bark-extract dose, duration or cycle is established?
4The cited evidence does not establish a dependable bark-extract dose, duration of benefit or cycling schedule. EFSA could not identify a daily bark-preparation intake without health concerns. The measured commercial yohimbine-content range above is a product analysis, not a tested regimen. Onset and elimination values from purified yohimbine cannot supply the missing extract-specific guidance.
References
- National Center for Complementary and Integrative Health. Yohimbe: Usefulness and Safety. Last updated May 2025.
- Cohen PA, Wang YH, Maller G, DeSouza R, Khan IA. Pharmaceutical quantities of yohimbine found in dietary supplements in the USA. Drug Testing and Analysis. 2016;8(3-4):357-369.
- Kearney T, Tu N, Haller C. Adverse drug events associated with yohimbine-containing products: a retrospective review of the California Poison Control System reported cases. Annals of Pharmacotherapy. 2010;44(6):1022-1029.
- EFSA Panel on Food Additives and Nutrient Sources Added to Food. Scientific Opinion on the evaluation of the safety in use of Yohimbe (Pausinystalia yohimbe). EFSA Journal. 2013;11(7):3302.
- European Commission. Commission Regulation (EU) 2015/403 of 11 March 2015 amending Annex III to Regulation (EC) No 1925/2006 as regards Ephedra species and Yohimbe.
- European Commission. Commission Regulation (EU) 2019/650 of 24 April 2019 amending Annex III to Regulation (EC) No 1925/2006 as regards Yohimbe.
- National Institute of Standards and Technology. A Standard for Quantifying Yohimbe in Dietary Supplements. Released April 17, 2024; updated February 4, 2025.
- Operation Supplement Safety. Yohimbe and Yohimbine in Dietary Supplement Products. Updated September 25, 2026.
- NIH Office of Dietary Supplements. Dietary Supplements for Weight Loss: Health Professional Fact Sheet. Yohimbe section. Updated May 18, 2022; accessed October 19, 2026.